Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy

Lei Jiang, Zheng Miao, Richard H. Kimura, Hongguang Liu, Jennifer R. Cochran, Cathy S. Culter, Ande Bao, Peiyong Li, Zhen Cheng

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Purpose: Cystine knot peptides (knottins) 2.5D and 2.5F were recently engineered to bind integrin receptors with high affinity and specificity. These receptors are overexpressed on the surface of a variety of malignant human tumor cells and tumor neovasculature. In this study, 2.5D and 2.5F were labeled with a therapeutic radionuclide, 177Lu, and the resulting radiopeptides were then evaluated as potential radiotherapeutic agents in a murine model of human glioma xenografts. Methods: Knottins 2.5D and 2.5F were synthesized using solid phase peptide synthesis, folded in vitro, and site-specifically coupled with 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴;-tetraacetic acid (DOTA) at their N terminus for 177Lu radiolabeling. The stability of the radiopeptides 177Lu-DOTA-2.5D and 177Lu-DOTA-2.5F was tested in both phosphate-buffered saline (PBS) and mouse serum. Cell uptake assays of the radiolabeled peptides were performed in U87MG integrin-expressing human glioma cells. The biodistribution studies of both 177Lu-DOTA-2.5D and 177Lu-DOTA-2.5F were examined in U87MG tumor-bearing athymic nu/nu mice. Radiation absorbed doses for the major tissues of a human adult male were calculated based on the mouse biodistribution results. Results: DOTA-2.5D and DOTA-2.5F were labeled with 177Lu at over 55% efficiency. High radiochemical purity for both radiocomplexes (> 95%) could be achieved after high performance liquid chromatography (HPLC) purification. Both radiopeptides were stable in PBS and mouse serum. Compared to 177Lu-DOTA-2.5D (0.39 and 0.26 %ID/g at 2 and 24 h, respectively), 177Lu-DOTA-2.5F showed much higher tumor uptake (2.16 and 0.78 %ID/g at 2 and 24 h, respectively). It also displayed higher tumor to blood ratios than that of 177Lu-DOTA-2.5D (31.8 vs 18.7 at 24 h and 52.6 vs 20.6 at 72 h). Calculation of radiodosimetry for 177Lu-DOTA-2.5D and 177Lu-DOTA-2.5F suggested that tumor and kidney were tissues with the highest radiation absorbed doses. Moreover, 177Lu-DOTA-2.5F had a higher tumor to kidney radiation absorbed dose ratio than that of 177Lu-DOTA-2.5D. Conclusion: Cystine knot peptides can be successfully radiolabeled with 177Lu for potential therapeutic applications. Knottin 2.5F labeled with 177Lu exhibits favorable distribution in murine U87MG xenograft model; thus, it is a promising agent for radionuclide therapy of integrin-positive tumors.

Original languageEnglish (US)
Pages (from-to)613-622
Number of pages10
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume38
Issue number4
DOIs
StatePublished - Apr 1 2011

Keywords

  • Lu
  • Cystine knot peptide
  • Integrin
  • Radionuclide therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Preliminary evaluation of <sup>177</sup>Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy'. Together they form a unique fingerprint.

  • Cite this